These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 16847942

  • 21. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
    Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S, Brin MF, Botox Detrusor Hyperreflexia Study Team.
    J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
    [Abstract] [Full Text] [Related]

  • 22. Editorial comment on: Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study.
    Burger M.
    Eur Urol; 2007 Nov; 52(5):1516-7. PubMed ID: 17574732
    [No Abstract] [Full Text] [Related]

  • 23. [Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
    Kosilov KV, Loparev SA, Krasnykh MA, Kosilova LV.
    Adv Gerontol; 2014 Nov; 27(1):149-55. PubMed ID: 25051773
    [Abstract] [Full Text] [Related]

  • 24. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG, Al-Buheissi S.
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [Abstract] [Full Text] [Related]

  • 25. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions.
    Bagi P, Biering-Sørensen F.
    Scand J Urol Nephrol; 2004 Apr; 38(6):495-8. PubMed ID: 15841785
    [Abstract] [Full Text] [Related]

  • 26. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Roumeguère T.
    Eur Urol; 2008 Oct; 54(4):916-7. PubMed ID: 18036722
    [No Abstract] [Full Text] [Related]

  • 27. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Kuo HC.
    Eur Urol; 2008 Oct; 54(4):915-6. PubMed ID: 18036725
    [No Abstract] [Full Text] [Related]

  • 28. Tolterodine for the treatment of overactive bladder.
    Salvatore S, Serati M, Bolis P.
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [Abstract] [Full Text] [Related]

  • 29. Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Serati M, Salvatore S, Uccella S, Cromi A, Khullar V, Cardozo L, Bolis P.
    Eur Urol; 2008 Oct; 54(4):911-5. PubMed ID: 18036728
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study.
    Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, Lafolie P.
    Scand J Urol Nephrol; 2007 Oct; 41(4):335-40. PubMed ID: 17763227
    [Abstract] [Full Text] [Related]

  • 31. [Urinary incontinence--treatment].
    Hader C, Welz-Barth A, Keller T.
    Dtsch Med Wochenschr; 2003 Apr 04; 128(14):750-2. PubMed ID: 12673531
    [No Abstract] [Full Text] [Related]

  • 32. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial.
    Silva C, Silva J, Ribeiro MJ, Avelino A, Cruz F.
    Eur Urol; 2005 Oct 04; 48(4):650-5. PubMed ID: 15961217
    [Abstract] [Full Text] [Related]

  • 33. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
    BJU Int; 2008 Nov 04; 102(9):1128-32. PubMed ID: 18647298
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.
    Jonas U, Höfner K, Madersbacher H, Holmdahl TH.
    World J Urol; 1997 Nov 04; 15(2):144-51. PubMed ID: 9144906
    [Abstract] [Full Text] [Related]

  • 35. [Administration of M-cholinoblockers after prostatic surgery].
    Golubtsova EN, Veliev EI.
    Urologiia; 2011 Nov 04; (5):46-9. PubMed ID: 22279787
    [Abstract] [Full Text] [Related]

  • 36. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z, 037 Study Group.
    Urology; 2008 Sep 04; 72(3):488-93. PubMed ID: 18639327
    [Abstract] [Full Text] [Related]

  • 37. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia.
    Van Kerrebroeck PE, Amarenco G, Thüroff JW, Madersbacher HG, Lock MT, Messelink EJ, Soler JM.
    Neurourol Urodyn; 1998 Sep 04; 17(5):499-512. PubMed ID: 9776013
    [Abstract] [Full Text] [Related]

  • 38. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study.
    Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G.
    J Urol; 2003 Jun 04; 169(6):2253-6. PubMed ID: 12771763
    [Abstract] [Full Text] [Related]

  • 39. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Olshansky B, Serra DB.
    Clin Pharmacol Ther; 2008 Feb 04; 83(2):231-2; author reply 233. PubMed ID: 18043690
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.